GT Apeiron Therapeutics

Targeting the cancer cell cycle with next generation CDK inhibitors

Shanghai, China and San Francisco, CA

About the company

A clinical stage small molecule biotech company targeting the cancer cell cycle with a portfolio of next generation CDK inhibitors to harness synthetic lethal interactions to advance the field. The lead asset GTAEXS-617 is a potential best-in-class CDK-7 inhibitor for the treatment of various transcriptionally addicted cancers.